Fundamental Data for ABBI

Abraxis BioScience, Inc. is an integrated global biopharmaceutical company dedicated to meeting the needs of critically ill patients. The company develops, manufactures and markets one of the broadest portfolios of injectable products and leverages revolutionary technology such as its nab platform to discover and deliver breakthrough therapeutics that transform the treatment of cancer and other life-threatening diseases. The company develops, manufactures, and distributes one of the broadest portfolios of injectable pharmaceuticals and develops revolutionary technology such as its proprietary nab technology platform to design and deliver breakthrough therapeutics that transform the treatment of cancer and other life-threatening diseases.

# Employees: 1864

Address: 11755 Wilshire Boulevard Suite 2000,Los Angeles,CA,USA

Phone: 310 883-1300

Fax: 310-826-8525

Website: www.abraxisbio.com

Email: webmaster@abraxisbio.com

Sector: Medical

Industry: MED-GENERIC DRG

Executive Officers

Patrick Soon Shiong M.D. (Chmn.; C.E.O.; Dir.)

Lisa Gopalakrishnan (Exec. V.P.; C.F.O.)

Kirk K. Calhoun (Dir.)

David S. Chen Ph.D. (Dir.)

Stephen D. Nimer M.D. (Dir.)

Dividend

Ex-Dividend Date: N/A

Annual Dividend: N/A

Current Dividend Yield: N/A

Dividend Paid (3 months): N/A

Indicated Dividend: N/A

Earnings

Last Earnings Date: 9/30/2007

Next Earnings Date(Expected): 3/10/2008

Mean EPS (Next Qtr): $0.22

Mean EPS (Year): $0.74

Mean Estimate(Long Term): $20.00

P/E Ratio(Based on EPS estimate): 29.010

Number of Estimates: 2

Shares Performance

Period	ABBI	Compare to S&P
YTD	-21.47 %	-22.42 %
4 Weeks	-10.54 %	-7.07 %
12 Weeks	0.75 %	-1.56 %

Shares Information

Analyst Coverage: Y

Avg Volume: 354424

Shares Outstanding: 159M

Market Cap: $3.43B

52 Week High: $29.24

52 Week Low: $20.02

P/E Ratio: 32.530

PEG Ratio: 1.450

Split: On 9/3/2003 ABBI split by factor of 1.500

Earnings Performance

EPS Growth in Last Quarter: -47.83 %

EPS Growth in Last Year: -33.33 %

Sales Growth in Last Quarter: -0.65 %

Sales Growth in Last Quarter: 18.62 %

Financials

Qtr Book Value: $3.09

Cash Flow/Share: $19.03

Change in Payout Ratio: -0.010

Price/Sales: 3.600